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Summary Sonothrombolysis is a novel therapy for recanalization of acute intracranial arterial
occlusion. So far, safety and efﬁcacy has been shown for transcranial ultrasound with diagnosticstroke;
Therapy;
Transcranial
ultrasound;
probes in combination with standard thrombolysis treatment. However, there are several new
developments including special designed ultrasound probes, microspheres for enhancement
of the thrombolytic effect of ultrasound and other new approaches. This review provides an
overview of current evidence from randomized controlled trials and perspectives on this topic.
© 2012 Elsevier GmbH.
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ntroduction
onothrombolysis has been introduced for treatment of
cute intracranial occlusions during the ﬁrst years of the last
ecade. Improved recanalization has been demonstrated
ith ‘‘diagnostic’’ transcranial ultrasound (US) in combi-
ation with standard intravenous (IV) thrombolysis with
ecombinant tissue-plasminogen activator (rtPA) in two ran-
omized trials [1,2]. A study with limited sample size on
iddle cerebral artery (MCA) main stem occlusion has indi-
ated that this method might be a possible alternative to
nterventional therapy [2]. The occurrence of an increased
ate of symptomatic hemorrhagic transformation of brain
nfarction after sonothrombolysis with diagnostic US has not
een conﬁrmed thus far [3]. In the absence of other ther-
pies (e.g., in cases of contraindication to thrombolytic
rugs or thrombus extraction), this method may serve as
n alternative treatment, as indicated by the ﬁndings of
small randomized study using transcranial color-coded
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Open access under CC BY-NC-ND license.onography (TCCS)-guided pulsed-wave (PW) US [4]. Novel
evelopments include microspheres-enhanced thrombolysis
or improved drug delivery and enhancement of microcircu-
ation [5,6]. A recent pilot study has tested the feasibility of
sing an intra-arterial high-energy US catheter for recanal-
zation [7]. Although many promising advances have been
ade in the ﬁeld of sonothrombolysis, ‘‘diagnostic’’ tran-
cranial US remains the only method that has been shown
o be effective and safe. The aim of this review is to pro-
ide an overview of conﬁrmed evidence and perspectives on
onothrombolysis for the treatment of acute ischemic stroke
AIS).
linical evidence
rom random observation to therapy
he thrombolytic effect of ‘‘diagnostic’’ transcranial US
n acute intracranial occlusion was discovered more than
0 years ago at 3 stroke therapy centers, independently of
ach other. At the Center for Noninvasive Brain Perfusion
tudies at the University of Texas-Houston Medical School,
hysicians noticed that patients receiving continuous tran-
cranial US monitoring for determination of rtPA-associated
Sonothrombolysis for stroke 15
Figure 1 Transcranial image in color-coded mode of transcranial color-coded sonography (TCCS). Proximal middle cerebral artery
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o(MCA) main stem occlusion (left) with complete recanalization
activator (rtPA) plus sonothrombolysis (right).
recanalization more frequently exhibited a favorable clini-
cal course in comparison to patients without monitoring [8].
Based on these results, a randomized, multicenter clinical
trial, known as the Combined Lysis of Thrombus in Brain
Ischemia Using Transcranial Ultrasound and Systemic tPA
(CLOTBUST) trial, was performed to study this effect. A sim-
ilar effect was observed with TCCS in the stroke unit at
the University of Lübeck, Germany [9] (Fig. 1). In contrast
to the multicenter CLOTBUST trial, this monocenter, ran-
domized study also included patients with contraindications
to rtPA. In addition, neurologists at the University Hospi-
tal Ostrava, Czech Republic, observed a similar effect in
patients with acute cerebral artery occlusion during exami-
nation with TCCS [10].
Results of randomized studies
The CLOTBUST trial included a total of 126 patients with
occlusion of the main segment of the stem or branches of
the MCA. All subjects were treated with standard IV rtPA
and were additionally randomized for a 2-h insonation with
transcranial Doppler (TCD). The primary endpoint (com-
plete recanalization or substantial clinical improvement)
m
s
i
nh after intravenous (IV) recombinant tissue-type plasminogen
as more frequently reached in the sonothrombolysis group
40%) than in the standard therapy group (30%). No signiﬁ-
ant differences were found in the clinical results obtained
fter 24 h and after 3months. However, a clear tendency for
unctional independence after 3months was detected in the
onothrombolysis group. The rate of symptomatic intracra-
ial hemorrhage (sICH) was the same for each group (4.8%)
1]. Some limitations of the CLOTBUST trial were the inclu-
ion of an inhomogeneous patient sample (MCA main stem
nd branch occlusions) and the deﬁnition of the primary end-
oint. The US imaging of the thrombus, carried out with
lind TCD sonography by means of a probe attached to the
ead, may also have been inadequate, particularly in branch
cclusions or occlusions of the main stem without residual
ow. Despite these limitations, this multicenter trial can be
onsidered a proof of principle study.
In the Lübeck study, patients were randomly selected to
eceive TCCS-guided PW mode US for 1 h. The color duplex
ode was used to improve the accuracy of focusing the US
n the thrombus. Patients with exclusively proximal MCA
ain stem occlusions without residual ﬂow who underwent
imultaneously insonation and rtPA standard treatment were
ncluded in the study. The homogeneity of the sample was
ot only a major strength of the study but also its weakness
1 J. Eggers
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Figure 2 Recanalization rates after 1 h from the Prolyse in
Acute Cerebral Thromboembolism II (PROACT II) study com-
pared with those from the sonothrombolysis with TCCS and rtPA
study. Partial/complete recanalization was deﬁned as follows:
Thrombolysis in Myocardial Infarction (TIMI) 2/3 in PROACT II,
and Thrombolysis in Brain Ischemia (TIBI) Doppler score [40]
2—3/4—5 in the sonothrombolysis with TCCS and rtPA study. For
the PROACT II study, 162 patients were 2:1 randomized for ther-
apy vs. control, for the sonothrombolysis study 37 patients were
randomized 1:1 for rtPA plus 1 h insonation (US) vs. rtPA alone.
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i.e., only a relatively low number of patients [n = 37] were
ncluded in this monocenter study). Similar to the ﬁndings of
he CLOTBUST trial, continuous insonation for 1 h (instead
f 2 h like in the CLOTBUST trial) resulted in signiﬁcantly
mproved recanalization (partial or complete recanaliza-
ion: 58% in the continuous insonation group vs. 22% in the
ontrol group). Additionally, an improvement in neurolog-
cal deﬁcits after 4 days, and a clear trend toward better
unctional outcome after 3months in patients was shown.
endencies for increased symptomatic cerebral bleeding (3
atients in the sonothrombolysis group vs. 1 patient in the
ontrol group) and increased hemorrhagic transformation of
nfarcts were also found in patients who underwent contin-
ous insonation [2]. A total of 15 patients were randomized
n the arm of the trial for patients with contraindications
o rtPA. Recanalization (all of them were partial recanal-
zations) after 1 h occurred only in the sonothrombolysis
roup (62.5% in the sonothrombolysis group vs. 0% in the
ontrol group). Signiﬁcant improvements in clinical course
fter 4 days and functional independence after 3months
ere found in 2 of 8 patients in the sonothrombolysis group
compared with none of the 7 patients in the control group)
4]. No sICHs occurred in the sonothrombolysis group. At
he end of the randomized trial, this treatment principle
as continued in the context of a clinical register. Currently
vailable data (obtained from a total of 116 patients with
CA main stem occlusions, with or without rtPA treatment)
onﬁrm these results (unpublished data).
onothrombolysis with TCCS in combination with
tPA: an alternative to interventional treatment?
or occlusions of the main intracranial arteries, IV throm-
olysis alone is probably not adequate to achieve early
ecanalization, which explains why interventional therapy,
ither intra-arterial thrombolysis or thrombus extraction, is
ften regarded as an alternative. However, in addition to
he yet unsatisfactory evidence attained from randomized
linical trials for these interventional therapies, there are
wo important limitations: the time delay to the start of
he intra-arterial intervention and the lack of availability of
hese types of interventional treatment in nonspecialized
enters. Sonothrombolysis as a tool to improve the effec-
iveness of IV thrombolysis may be a promising alternative
ption. A comparison of the published randomized data and
hose from the randomized study of intra-arterial thrombol-
sis, known as Prolyse in Acute Cerebral Thromboembolism
I (PROACT II) [11], revealed very similar recanalization
ates, although more severe occlusions were treated in the
onothrombolysis study (proximal MCA-M1 occlusions in con-
rast to M1 and M2 branch occlusions in PROACT II). As shown
n Fig. 2, rates of recanalization in the PROACT II study
ere quite similar to those obtained in the sonothrombolysis
ith TCCS and rtPA study. The PROACT II study random-
zed patients with MCA main stem or M2 branch occlusions
ithin a 6-h time window for intra-arterial thrombolysis
ith pro-urokinase. The sonothrombolysis with TCCS andV rtPA study randomized patients with proximal MCA main
tem occlusions without residual ﬂow (including patients
ith additional ipsilateral internal carotid artery occlusion)
ithin a 3-h time window for 1 h of continuous insonation. As
t
t
p
chown in Fig. 3, comparable outcome results after 3months
3—4months in PROACT II) were obtained for the sonothrom-
olysis with TCCS and IV rtPA group and the pro-urokinase
reatment group. The strong tendency toward a worse
utcome for patients in the IV rtPA group without sonothrom-
olysis compared with those in the PROACT II control group
ay indicate that patients in the Lübeck randomized study
ay have been more severely affected than those in the
ROACT II study.
imitations of sonothrombolysis
he lack of a temporal bone window is one main limitation
f sonothrombolysis. Research studies have revealed that
he frequency of an insufﬁcient temporal sound window for
CCS can vary from 8% [12] to 27% [13]. On the other hand,
lso the interventional therapy may not be applicable for all
atients. A common limitation of interventional therapy is
he lack of patency of the proximal carotid artery. Data from
he own register of MCA-M1 occlusions have revealed the
resence of an additional proximal occlusion of the internal
arotid artery in 23% of patients (unpublished data).
Sonothrombolysis for stroke
Figure 3 Functional results after 90 days (in the Prolyse
in Acute Cerebral Thromboembolism II [PROACT II] collec-
tive, 90—120 days) as measured on the modiﬁed Rankin scale
(mRS). Median National Institutes of Health Stroke Scale (NIHSS)
scores on inclusion: PROACT II, 17 for control group and 17
for pro-urokinase group; sonothrombolysis with transcranial
color-coded sonography (TCCS) and recombinant tissue-type
plasminogen activator (rtPA) study, 18 for IV rtPA and 18 for
IV rtPA plus ultrasound (US). The percentages in the bars give
the rate of mRS scores (0—1) or the mortality at 90 days
(90—120 days in PROACT II). Number of randomized patients
in PROACT II, 162; in the sonothrombolysis study, 37. Rate of
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tsymptomatic intracranial hemorrhage (sICH): 10% in the pro-
urokinase group, 15% in the sonothrombolysis group. Differences
were not statistically signiﬁcant.
Meta-analysis of clinical results of
sonothrombolysis
A meta-analysis conducted by Tsivgoulis et al. [3] on
sonothrombolysis with transcranial US (TCCS or TCD)
included over 400 patients. They found that in comparison to
patients with rtPA treatment alone, patients who underwent
sonothrombolysis had a 3 times higher chance for complete
recanalization and a 2 times higher chance for non-disability
after 3months. There was no evidence for increased risk of
cerebral bleeding with US treatment.
From bedside to bench: experimental
evidence
When the thrombolytic effect of ‘‘diagnostic’’ transcranial
US was clinically observed for the ﬁrst time, no experimen-
tal data on the effect of high-frequency, low-energy PW US
on thrombolysis were available at the time. However, dur-
ing the 1990s (after much time had passed since the ﬁrst
description of the thrombolytic effect of US in the late
1970s [14]), in vitro studies using high-frequency (1MHz)
and high-energy (spatial peak temporal average intensity
[ISPTA] of 2W/cm2) US demonstrated improved US-mediated
U
u
d
c17
inding of rtPA to ﬁbrin, as well as reversible disintegra-
ion of ﬁbrin without thrombolytics [15]. By contrast, in the
übeck study, the transducers for ‘‘diagnostic’’ transcranial
se employed frequencies between 1.8 and 2.5MHz and had
ISPTA of 179/cm2, and most of the energy was absorbed by
he skull. For neurological disorders, only two in vitro studies
n the transcranial use of US for acceleration of thrombolysis
ere available at this time: These studies showed the effect
f low-frequency US in combination with a thrombolytic on
brin-rich thrombi [16,17]. However, the US used in these
wo studies differed substantially from the diagnostic US of
probe for TCCS: The frequencies used in the in vitro studies
ere in the range of 33—211 kHz, leading to good penetra-
ion of emitted US energy through the skull (e.g., by 40% in
he Akiyama et al. [16] study). In comparison, up to 90% of
nergy from a high-frequency (1.8—2.5MHz) ‘‘diagnostic’’
ranscranial US probe was absorbed by the skull [18,19]. To
btain more information about the thrombolytic effect of
‘diagnostic’’ transcranial US, corresponding in vitro studies
ere done. In addition to the effect on the thrombolysis of
hole venous blood clots, the effect on platelet-rich clots
PRCs) was investigated. The effect of US in combination
ith abciximab, the glycoprotein IIb/IIIa receptor inhibitor,
as also examined and compared with the effect of rtPA.
ne main ﬁnding was that sonothrombolysis in combina-
ion with rtPA had a greater effect on whole venous blood
lots and PRCs than sonothrombolysis in combination with
bciximab. Because sonothrombolysis in combination with
bciximab produced very disappointing results, including a
eak effect on PRCs, this combination could not be rec-
mmended [20,21]. A study by Pfaffenberger et al. [19],
hich compared the impact of duplex-Doppler, continuous
ave-Doppler, and PW-Doppler on rtPA-mediated thrombol-
sis, found that only the PW mode signiﬁcantly accelerated
tPA-mediated thrombolysis.
erspectives for sonothrombolysis
perator-independent device for sonothrombolysis
multicenter, randomized clinical trial will be launched to
valuate the safety and applicability of a novel operator-
ndependent device for sonothrombolysis. A total of 900
atients who receive standard IV rtPA treatment will be
andomized for 2-MHz PW US vs. sham treatment. The pri-
ary outcome endpoint will be functional independence
fter 3months, and sICH will be assessed as the primary
afety endpoint [22]. The introduction of a semi-automatic
ovel device for sonothrombolysis may overcome the disad-
antages of conventional diagnostic US probes, which are
onsidered time-consuming and operator intensive.
ther types of US
he results of previously conducted randomized clinical
rials were based on the randomly observed effects of
ranscranial imaging generated by commercial diagnostic
S devices. An early attempt to enhance thrombolysis by
sing US probes dedicated for optimized sonothrombolysis
id not yield promising results. A multicenter, randomized
linical trial investigating the effectiveness of a specially
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eveloped ‘‘sonothrombolysis probe’’ with a higher energy
nd lower frequency for improved penetration of the skull
Transcranial Low-frequency Ultrasound-mediated Throm-
olysis in Brain Ischemia [TRUMBI] study) unfortunately
esulted in a higher rate of sICH [23]. Cerebral bleeding
fter treatment also occurred on the opposite side of the
rain infarction, suggesting a causal link to the substantially
igher energy and lower frequency of the ‘‘sonothrombolysis
robe’’ compared with the energy of diagnostic US probes.
n vivo experiments evaluating the therapeutic efﬁcacy and
afety of using highly energetic, low-frequency (20 kHz) US
n treating rats with an embolic MCA occlusion showed an
ncreased incidence of cerebral edema [24,25], thus indi-
ating the unsuitability of this kind of US for clinical use. So
ar, ‘‘diagnostic’’ transcranial US remains the only form of
S appropriate for sonothrombolysis.
ndovascular sonothrombolysis: results from a
ilot study
koloudik et al. [7] performed a pilot study on 9 patients who
ad suffered an AIS with acute MCA or basilar artery occlu-
ion and undergone endovascular sonothrombolysis within
n 8-h time window from symptom onset. For this purpose,
3F microcatheter with a US probe of 2.05—2.35MHz was
sed. Complete recanalization at the end of treatment was
chieved in one third of patients, and partial recanalization
ccurred in an additional 44% of patients at the end of the
rocedure. At admission, the National Institutes of Health
troke Scale (NIHSS) scores were in the range of 10—33
median, 19.0). At 3months, 4 (44%) patients were func-
ionally independent (modiﬁed Rankin Scale [mRS] score,
—3; median mRS score, 4). No sICHs occurred for 24 h after
ndovascular sonothrombolysis until a control computed
omography (CT) scan at 24 h. These researchers concluded
hat this endovascular system might serve as a new treat-
ent option for patients suffering from acute stroke.
S can control embolus growth—–can transcranial
S prevent early reocclusion?
he thrombolytic effect of US has generally been regarded
s a tool for improving recanalization. However, as several
S follow-up studies have shown, reocclusion of a vessel
fter recanalization can occur in 20% or more (up to 29%) of
atients after rtPA treatment [1,26]. Sawaguchi et al. [27]
ecently reported interesting results from a novel use of US
reatment in AIS. They found that continuous US (500 kHz,
.72—0.28W/cm2) signiﬁcantly suppressed thrombus growth
n vitro. Based on their ﬁndings, these researchers suggested
ow-intensity, low-energy US as a possible simple and safe
ool to prevent reocclusion of intracranial vessels after rtPA
reatment.
hat is the most effective US for
onothrombolysis? Systemic evaluation using
tandardized experimental settings
etermining the most efﬁcient US settings for sonothrombol-
sis is complicated by the fact that there is a tremendous
v
f
y
mJ. Eggers
umber of possible combinations of its parameters. Wang
t al. [28] presented results from an in vitro experiment
or the systematic and rapid evaluation of the thrombolytic
ffect of 500-kHz US as the ultrasonic spatial intensity
ncreased from 0.1 to 0.7mW/cm2. For this purpose, ﬂat dis-
oid clots were simultaneously made in specially designed
ells with a thin polycarbonate base that is transparent
o light and reﬂects little US. The extent of clot lysis was
utomatically measured by means of light absorbance at
wavelength of 412 nm using a spectrometer before and
fter thrombolytic treatment. This method allowed the
esearchers to measure automatically a total of 200 posi-
ions within minutes, representing a throughput about 100
imes as large as that of conventional methods.
agnetic resonance imaging (MRI)-guided US for
onothrombolysis
agnetic resonance-guided focused ultrasound (MRgFUS) is a
ovel method for optimizing US treatment. In general, mag-
etic resonance imaging (MRI) enables the adjustment of
he US beam, based on differences in temperature mea-
urements in the targeted parenchyma. For the purpose
f sonothrombolysis, preliminary steps have involved using
n vitro models with human skull and porcine brain. In future,
t may be possible to detect the thrombus within the vessel,
o focus the US beam on this target, and make corrections
o the US beam so as to avoid side effects of US caused by
istortion and shifting of the human skull [29,30].
icrospheres for enhancement of
onothrombolysis: current state and new
evelopments
nother way of enhancing the effect of sonothrom-
olysis involves the use of microspheres. Commercially
anufactured ultrasonic contrast ampliﬁers have been
sed in several studies: SonoVue®, which consists of sul-
ur hexaﬂuoride-ﬁlled microbubbles of phospholipids, and
evovist®, a granulate of galactose and palmitic acid, which
inds to micrometer-sized air bubbles. Following IV injec-
ion, they take energy on under inﬂuence of US, and by
scillation or rupture, this energy is released again, which
einforces the US effectiveness. Various experiments have
hown the effectiveness of this method without an increase
n the intracranial bleeding rate, which has been demon-
trated in vivo. Molina et al. [31] showed an improvement
y intermittent bolus injection of Levovist® in addition to
PA treatment plus 2-h insonation with TCD monitoring. A
imilar study was conducted by Perren et al. [32] in which
atients who had suffered from an MCA stroke underwent
V rtPA thrombolysis and 2-MHz TCCS monitoring for 1 h
ith SonoVue®, resulting in clinical improvement in these
atients. No additional intracranial bleedings were noted
n these studies. In the transcranial ultrasound in clinical
onothrombolysis (TUCSON) randomized clinical trial, intra-
enously applied microspheres, which had been developed
or the purpose of strengthening the effect of sonothrombol-
sis, were clinically tested [5]. This dose-escalation study of
icrospheres showed increased bleeding in the second dose
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tier, prompting the sponsor of the study to discontinue this
approach.
Microspheres with abciximab for better thrombus
binding and identiﬁcation and improved
sonothrombolysis
In vivo molecular imaging of the human thrombus can be
carried out with microspheres conjugated with abciximab,
a glycoprotein IIb/IIIa receptor inhibitor that is involved in
ligand targeting of the thrombus. In vitro experiments have
shown that improved binding of microspheres to the clot
enhances sonothrombolysis [33,34].
Nanodroplet-enhanced sonothrombolysis
In their 2011 study, Shimizu et al. [35] reported prelimi-
nary results from an in vivo animal safety evaluation in vivo
experiment with superheated perﬂuorocarbon nanodroplets
(SPNs). When triggered by US, these nanodroplets turn
into microbubbles. During this in vivo experiment, rabbits
received either an IV injection of SPNs or a placebo without
additional insonation. Within an hour after administration
of SPNs, 4 cases showed a reversible change in respira-
tion; 1 animal showed transient horizontal nystagmus about
20min after administration of SPNs. Following euthanasia,
no neuropathological damage or histological damage could
be shown in any organ sample from any of the animals
included in the study. The biochemical blood examination
revealed no signiﬁcant differences between the SPN-treated
group and the placebo group. These researchers plan to con-
duct a study investigating the SPN-assisted sonothrombolytic
effect of 500-kHz US exposure.
US-targeted drug delivery to the brain
In addition to enhancing sonothrombolysis, the combi-
nation of transcranial US and microspheres may have
another purpose—–that is, facilitating the delivery of drugs
across the blood—brain barrier (BBB). Substances or drugs
(e.g., large-molecule agents such as monoclonal antibodies,
recombinant proteins, and gene therapeutics) that would
be potentially useful for treatment of a variety of central
nervous system disorders cannot penetrate the BBB. New
developments have shown that noninvasive, targeted, US-
induced disruption of the BBB could facilitate drug delivery.
Transcranial-focused US penetrates the skull, thus prevent-
ing the need for trepanation. Targeting of the US beam can
also be optimized by MRI [36—38].
Improvement of microcirculation
In addition to recanalization, microcirculation of ischemic
brain parenchyma can be a target for transcranial US treat-
ment of AIS. This possible effect of US was ﬁrst described by
Suchkova et al. [39]; this effect may also be achieved with
US combined with microspheres [6].19
onclusion
everal clinical studies have shown that sonothromboly-
is using ‘‘diagnostic’’ transcranial US in combination with
tPA improves recanalization of an acute intracranial artery
cclusion. The chance of a favorable functional outcome
fter 3months is doubled with this method of treatment
hen compared with rtPA treatment alone. TCCS has sev-
ral advantages (e.g., visualization of an occlusion in a
horter insonation time) over TCD; thus, it is considered
more advanced tool. Although results of sonothrombol-
sis with TCCS have thus far been based on limited sample
ize, this method seems to provide a degree of effective-
ess in achieving early recanalization of proximal MCA main
tem occlusion that is similar to that provided by intra-
rterial thrombolysis. For this reason, sonothrombolysis
sing TCCS should be considered an alternative treatment to
ntra-arterial recanalization procedures. A tendency toward
ncreased cerebral infarction bleeding in patients treated
ith sonothrombolysis in combination with IV rtPA has not
een conﬁrmed thus far. Sonothrombolysis with TCCS alone
n cases of contraindication for rtPA administration should
e considered as a treatment option. Several studies have
hown that microspheres may have a dual role: They may be
sed to enhance the effect of sonothrombolysis and assist in
argeted drug delivery. To date, transcranial US has mainly
een developed for diagnostic purposes. Several experimen-
al studies have been conducted or are being undertaken
o optimize US settings for sonothrombolysis. A need still
xists to determine the optimal US frequency and energy so
s to achieve the safest and most effective form of US for
onothrombolysis.
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